Last reviewed · How we verify
prostate cancer vaccine ONY-P1
prostate cancer vaccine ONY-P1 is a Biologic drug developed by Kael-GemVax Co., Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | prostate cancer vaccine ONY-P1 |
|---|---|
| Sponsor | Kael-GemVax Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- prostate cancer vaccine ONY-P1 CI brief — competitive landscape report
- prostate cancer vaccine ONY-P1 updates RSS · CI watch RSS
- Kael-GemVax Co., Ltd. portfolio CI
Frequently asked questions about prostate cancer vaccine ONY-P1
What is prostate cancer vaccine ONY-P1?
prostate cancer vaccine ONY-P1 is a Biologic drug developed by Kael-GemVax Co., Ltd..
Who makes prostate cancer vaccine ONY-P1?
prostate cancer vaccine ONY-P1 is developed by Kael-GemVax Co., Ltd. (see full Kael-GemVax Co., Ltd. pipeline at /company/kael-gemvax-co-ltd).
What development phase is prostate cancer vaccine ONY-P1 in?
prostate cancer vaccine ONY-P1 is in Phase 2.